[The contribution of high-throughput sequencing in malignant hematological disorders]

THE CONTRIBUTION OF HIGH-THROUGHPUT SEQUENCING IN MALIGNANT HEMATOLOGICAL DISORDERS. The development of cancers is largely attributed to somatic mutations in genes, imparting a selective advantage to cells, allowing for their progressive expansion. Thanks to the rise of high-throughput sequencing technologies, it is now possible to precisely characterize the genetic events that have contributed to tumorigenesis and extract clinically relevant information from them. After outlining the technical and bioinformatic steps required for these analyses, we present their primary consensus indications for positive diagnosis, prognostic evaluation, and/or therapeutic target discovery in malignant hematological disorders. The prospects that new sequencing techniques off er for diagnosis in the years to come are also presented.